immunotherapy

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa

Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV CAIRO, EGYPT; BERLIN, GERMANY;…

2 months ago

FIRST CANCER PATIENT SCREENED USING ELEPHAS LIVE PLATFORM AT inDNA LIFE SCIENCES in INDIA

Elephas Live™ Platform to Help Increase Access to Immunotherapy for Cancer Patients in India MADISON, Wis., Oct. 9, 2025 /PRNewswire/…

2 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

2 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology…

2 months ago

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

Using Sapu Nano’s proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenouslySYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN –…

2 months ago

Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay

PENSACOLA, Fla., Oct. 7, 2025 /PRNewswire/ -- Circulogene today announced the national launch of OncoGenDx, an innovative tissue-based comprehensive genomic…

2 months ago

Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025

NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3…

2 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing…

2 months ago